Comparative Pharmacology
Head-to-head clinical analysis: DITATE DS versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITATE DS versus ORTIKOS.
DITATE-DS vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug).
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid